Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

作者：Burke John M^*; van der Jagt Richard H C; Kahl Brad S; Wood Peter; Hawkins Tim E; MacDonald David; Hertzberg Mark; Simpson David; Craig Michael; Kolibaba Kathryn; Issa Samar; Munteanu Mihaela; Victor Timothy W; Flinn Ian W

来源：Clinical Lymphoma Myeloma & Leukemia, 2016, 16(4): 182-+.

DOI：10.1016/j.clml.2016.01.001

• BRIGHT trial
• EORTC QLQ-C30
• First-line therapy
• Patient-reported outcomes
• Phase 3

Comparative chemotherapy-related quality of life data are lacking. Bendamustine-rituximab (BR) demonstrated noninferiority to R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone)/R-CVP (rituximab/cyclophosphamide/vincristine/prednisone) in first-line advanced indolent non-Hodgkin and mantle cell lymphomas. Patients receiving BR reported improvement across many domains, with a few exceptions, of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30.
Background: We previously reported results of the phase III, randomized, noninferiority trial comparing bendamustine-rituximab (BR) with standard R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone)/ R-CVP (rituximab/cyclophosphamide/vincristine/prednisone) in previously untreated advanced indolent non-Hodgkin and mantle cell lymphomas. Here we report health-related quality of life (HRQOL) results from the trial. Methods: HRQOL, as measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), was a secondary end point. Differences between group means in global health status (GHS), 5-item functioning, and 9 symptoms/single-item measures at week 1 of cycle 1 and end-of-cycles 3 and 6 were examined using the screening (baseline) score as a covariate in analysis of covariance. Results: Overall EORTC QLQ-C30 compliance was 75.2%, 89.5%, and 89.9% at week 1 of cycle 1 and end-of-cycles 3 and 6, respectively. Patients treated with BR reported improvements in Cognitive Functioning, Physical Functioning, Social Functioning, Emotional Functioning, and GHS as well as reduction in dyspnea, constipation, and fatigue at some, but not all, time points. Patients treated with standard therapy reported less nausea/vomiting at one time point. Conclusion: Compared with patients treated with standard therapy, patients treated with BR reported better quality of life in several areas.

• 出版日期2016-4